Legal & General Group Plc Buys 3,385 Shares of BioTelemetry, Inc. (NASDAQ:BEAT)

Legal & General Group Plc lifted its stake in BioTelemetry, Inc. (NASDAQ:BEAT) by 6.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 55,503 shares of the medical research company’s stock after buying an additional 3,385 shares during the quarter. Legal & General Group Plc owned approximately 0.17% of BioTelemetry worth $1,831,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. FNY Partners Fund LP boosted its position in BioTelemetry by 74.1% during the third quarter. FNY Partners Fund LP now owns 7,000 shares of the medical research company’s stock worth $231,000 after purchasing an additional 2,980 shares in the last quarter. ETRADE Capital Management LLC raised its holdings in shares of BioTelemetry by 21.8% during the third quarter. ETRADE Capital Management LLC now owns 32,570 shares of the medical research company’s stock valued at $1,075,000 after acquiring an additional 5,838 shares during the last quarter. Icon Advisers Inc. Co. raised its holdings in shares of BioTelemetry by 29.4% during the third quarter. Icon Advisers Inc. Co. now owns 146,597 shares of the medical research company’s stock valued at $4,838,000 after acquiring an additional 33,319 shares during the last quarter. Pembroke Management LTD raised its holdings in shares of BioTelemetry by 63.9% during the third quarter. Pembroke Management LTD now owns 449,300 shares of the medical research company’s stock valued at $14,827,000 after acquiring an additional 175,200 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC raised its holdings in shares of BioTelemetry by 24.3% during the third quarter. Thompson Siegel & Walmsley LLC now owns 538,107 shares of the medical research company’s stock valued at $17,758,000 after acquiring an additional 105,345 shares during the last quarter. Hedge funds and other institutional investors own 82.34% of the company’s stock.

BioTelemetry, Inc. (BEAT) opened at $33.15 on Friday. The stock has a market capitalization of $1,020.00, a price-to-earnings ratio of 25.31, a P/E/G ratio of 1.40 and a beta of 0.53. BioTelemetry, Inc. has a fifty-two week low of $21.05 and a fifty-two week high of $39.20. The company has a quick ratio of 1.48, a current ratio of 1.60 and a debt-to-equity ratio of 0.75.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, November 7th. The medical research company reported $0.16 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The company had revenue of $81.02 million during the quarter, compared to analysts’ expectations of $82.10 million. During the same quarter last year, the business posted $0.21 earnings per share. The company’s revenue for the quarter was up 52.7% on a year-over-year basis. research analysts anticipate that BioTelemetry, Inc. will post 0.83 EPS for the current year.

A number of brokerages have commented on BEAT. BidaskClub raised BioTelemetry from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 19th. SunTrust Banks assumed coverage on BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 price target for the company. Raymond James Financial assumed coverage on BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 price target for the company. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. Finally, Dougherty & Co reissued a “buy” rating and set a $40.00 target price on shares of BioTelemetry in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. BioTelemetry currently has a consensus rating of “Hold” and a consensus target price of $42.86.

ILLEGAL ACTIVITY NOTICE: “Legal & General Group Plc Buys 3,385 Shares of BioTelemetry, Inc. (NASDAQ:BEAT)” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/14/legal-general-group-plc-buys-3385-shares-of-biotelemetry-inc-beat-updated-updated.html.

BioTelemetry Profile

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply